Role of biochemical markers in the management of osteoporosis
(2001) In Best Practice & Research: Clinical Rheumatology 15(3). p.385-400- Abstract
- Several serum and urine biochemical markers of bone resorption and formation have been developed. Biochemical bone markers have been used as intermediate end-points in all major studies of anti-osteoporotic therapies. Bone resorption markers, in particular, may add an independent, predictive value to the assessment of bone loss and fracture risk. There are also potential advantages in monitoring anti-osteoporotic treatment in the short-term in addition to bone densitometry, to rapidly identify non-responders to therapy, or non-compliance. Despite these recent advances, until now bone markers have simply been very useful research tools, with their clinical utility being limited by intra-individual and diurnal variability. However, the... (More)
- Several serum and urine biochemical markers of bone resorption and formation have been developed. Biochemical bone markers have been used as intermediate end-points in all major studies of anti-osteoporotic therapies. Bone resorption markers, in particular, may add an independent, predictive value to the assessment of bone loss and fracture risk. There are also potential advantages in monitoring anti-osteoporotic treatment in the short-term in addition to bone densitometry, to rapidly identify non-responders to therapy, or non-compliance. Despite these recent advances, until now bone markers have simply been very useful research tools, with their clinical utility being limited by intra-individual and diurnal variability. However, the probability of the true bone mineral density response to hormone replacement therapy for the individual patient may be predicted using algorithms based on a spectrum of cut-off bone marker levels with varying false positive and negative rates. Thus, the transition of biochemical bone markers into everyday clinical practice may be rapidly approaching. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1136739
- author
- Ebeling, P and Åkesson, Kristina LU
- organization
- publishing date
- 2001
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- biochemical bone markers, fracture risk, therapy, bone density, non-responders
- in
- Best Practice & Research: Clinical Rheumatology
- volume
- 15
- issue
- 3
- pages
- 385 - 400
- publisher
- Elsevier
- external identifiers
-
- scopus:0034879092
- ISSN
- 1532-1770
- DOI
- 10.1053/berh.2001.0156
- language
- English
- LU publication?
- yes
- id
- 4f2db317-ae5c-4a36-a172-13348bc0bfc9 (old id 1136739)
- alternative location
- http://europepmc.org/abstract/MED/11485336
- date added to LUP
- 2016-04-01 12:26:09
- date last changed
- 2025-04-04 15:18:54
@article{4f2db317-ae5c-4a36-a172-13348bc0bfc9,
abstract = {{Several serum and urine biochemical markers of bone resorption and formation have been developed. Biochemical bone markers have been used as intermediate end-points in all major studies of anti-osteoporotic therapies. Bone resorption markers, in particular, may add an independent, predictive value to the assessment of bone loss and fracture risk. There are also potential advantages in monitoring anti-osteoporotic treatment in the short-term in addition to bone densitometry, to rapidly identify non-responders to therapy, or non-compliance. Despite these recent advances, until now bone markers have simply been very useful research tools, with their clinical utility being limited by intra-individual and diurnal variability. However, the probability of the true bone mineral density response to hormone replacement therapy for the individual patient may be predicted using algorithms based on a spectrum of cut-off bone marker levels with varying false positive and negative rates. Thus, the transition of biochemical bone markers into everyday clinical practice may be rapidly approaching.}},
author = {{Ebeling, P and Åkesson, Kristina}},
issn = {{1532-1770}},
keywords = {{biochemical bone markers; fracture risk; therapy; bone density; non-responders}},
language = {{eng}},
number = {{3}},
pages = {{385--400}},
publisher = {{Elsevier}},
series = {{Best Practice & Research: Clinical Rheumatology}},
title = {{Role of biochemical markers in the management of osteoporosis}},
url = {{http://dx.doi.org/10.1053/berh.2001.0156}},
doi = {{10.1053/berh.2001.0156}},
volume = {{15}},
year = {{2001}},
}